Sampat Ingale
Senior Director - Peptide & Protein Chemistry Biohaven Ltd.
Sampat Ingale is Senior Director of Peptide and Protein Chemistry at Biohaven, leading innovation across peptide engineering, bioconjugation, and complex therapeutic modalities. He brings over two decades of experience spanning Biohaven, Flagship Pioneering, Merck, Novo Nordisk, Sorrento Therapeutics, and The Scripps Research Institute. Sampat has spearheaded the development of site‑specific conjugation technologies, peptide and macrocyclic platforms, lipid nanoparticle targeting strategies, and diverse antigen presentation systems. His work has enabled advances in ADC design, enzymatic and chemical conjugation, and peptide-based biologics. With deep expertise in synthetic chemistry, analytical workflows, and cross‑functional leadership, he continues to drive next‑generation biotherapeutic innovation.
Seminars
- Leveraging conserved Fc N-glycans and orthogonal conjugation chemistries to create spatially defined attachment sites for dual payload incorporation, enabling homogeneous, structurally stable ADCs Fc integrity, and pharmacokinetic performance
- Integrating highly stable, irreversible linker technologies with controlled DAR to independently modulate two mechanistically distinct payloads, minimizing premature release, reducing systemic toxicity, and maintaining payload balance
- Applying Biohaven’s MATE™ platform and advanced conjugation strategy to nextgeneration programs such as BHV-1510 and BHV-1530, supporting dual-payload designs that combine synergistic cytotoxic mechanisms, improved safety margins, and enhanced anti-tumor durability
